Endocan is a key player in cardiovascular disease: A review
- Authors: Alieva A.M.1, Reznik E.V.1, Baykova I.E.1, Teplova N.V.1, Makeeva L.M.1, Voronkova K.V.1, Khadzhieva N.K.2, Modestova A.V.1, Totolyan G.G.1, Valiev R.K.3, Li A.M.4, Kotikova I.A.1, Nikitin I.G.1
-
Affiliations:
- Pirogov Russian National Research Medical University
- Central Clinical Hospital “RZD-Medicine”
- Loginov Moscow Clinical Scientific Center
- MEDSI Group of Companies
- Issue: Vol 25, No 1 (2023): Cardiovascular diseases
- Pages: 20-28
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131632
- DOI: https://doi.org/10.26442/20751753.2023.1.202079
- ID: 131632
Cite item
Full Text
Abstract
In recent years, the attention of scientists has been actively focused on studying the role of endocan as a biological marker of endothelial dysfunction in cardiovascular diseases. Until recent years, endocan has been studied in acute kidney injury, chronic kidney disease, and renal replacement therapy. Endocan, formerly known as endothelial cell-specific molecule-1, is a soluble dermatan sulfate proteoglycan expressed and secreted into the circulation from endothelial cells. Currently available studies demonstrate the diagnostic and prognostic value of endocan evaluation in cardiovascular pathology. It is expected that further scientific and clinical studies will demonstrate the possibilities of using endocan as an additional laboratory tool for diagnosing and assessing the prognosis in patients with a cardiac profile. Drug regulation of endocan concentration and expression may be a promising target for the treatment of cardiac and vascular pathology.
Full Text
##article.viewOnOriginalSite##About the authors
Amina M. Alieva
Pirogov Russian National Research Medical University
Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN-code: 2749-6427
Cand. Sci. (Med.)
Russian Federation, MoscowElena V. Reznik
Pirogov Russian National Research Medical University
Email: elenaresnik@gmail.com
ORCID iD: 0000-0001-7479-418X
SPIN-code: 3494-9080
D. Sci. (Med.), Prof.
Russian Federation, MoscowIrina E. Baykova
Pirogov Russian National Research Medical University
Email: 1498553@mail.ru
ORCID iD: 0000-0003-0886-6290
SPIN-code: 3054-8884
Cand. Sci. (Med.)
Russian Federation, MoscowNatalia V. Teplova
Pirogov Russian National Research Medical University
Email: 1498553@mail.ru
ORCID iD: 0000-0002-7181-4680
D. Sci. (Med.), Prof.
Russian Federation, MoscowLiudmila M. Makeeva
Pirogov Russian National Research Medical University
Email: mila-mm@yandex.ru
ORCID iD: 0000-0003-0755-4869
Assistant
Russian Federation, MoscowKira V. Voronkova
Pirogov Russian National Research Medical University
Email: kiravoronkova@yandex.ru
ORCID iD: 0000-0003-1111-6378
SPIN-code: 1636-7627
D. Sci. (Med.)
Russian Federation, MoscowNyurzhanna Kh. Khadzhieva
Central Clinical Hospital “RZD-Medicine”
Email: nurzhanna@yandex.ru
ORCID iD: 0000-0002-5520-281X
SPIN-code: 2520-8520
Cand. Sci. (Med.)
Russian Federation, MoscowAnna V. Modestova
Pirogov Russian National Research Medical University
Email: a.modestowa@yandex.ru
Cand. Sci. (Med.)
Russian Federation, MoscowGaiane G. Totolyan
Pirogov Russian National Research Medical University
Email: tgg03@mail.ru
ORCID iD: 0000-0002-9922-5845
Cand. Sci. (Med.)
Russian Federation, MoscowRamiz K. Valiev
Loginov Moscow Clinical Scientific Center
Email: radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
Cand. Sci. (Med.)
Russian Federation, MoscowAlexander M. Li
MEDSI Group of Companies
Email: steve-sk8@yandex.ru
ORCID iD: 0000-0001-6809-5227
Ultrasound Doctor
Russian Federation, MoscowIrina A. Kotikova
Pirogov Russian National Research Medical University
Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
Student
Russian Federation, MoscowIgor G. Nikitin
Pirogov Russian National Research Medical University
Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- World Health Organization. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. World Health Organization. Geneva, Switzerland, 2020.
- Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов – членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101 [Kopyeva KV, Grakova EV, Teplyakov AT. New markers of heart failure: implications for the diagnosis and prognosis of NT-proBNP and interleukin receptors, members of the ST2 family. Complex Problems of Cardiovascular Diseases. 2018;7(1):94-101 (in Russian)]. doi: 10.17802/2306-1278-2018-7-1-94-101
- Алиева А.М., Резник Е.В., Гасанова Э.Т., и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Alieva AM, Reznik EV, Gasanova ET, et al. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45 (in Russian)]. doi: 10.20514/2226-6704-2018-8-5-333-345
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehw128
- Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Значение копептина в диагностике и прогнозе течения сердечно-сосудистых заболеваний. Клиническая медицина. 2020;98(3):203-9 [Alieva AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of the course of cardiovascular diseases. Clinical Medicine. 2020;98(3):203-9 (in Russian)]. doi: 10.30629/0023-2149-2020-98-3-203-209
- Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular diseases. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. doi: 10.26442/20751753.2020.5.200186
- Алиева А.М., Пинчук Т.В., Алмазова И.И., и др. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021;23(6):522-6 [Alieva AM, Pinchuk TV, Almazova II, et al. Clinical significance of determination of ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian)]. doi: 10.26442/20751753.2021.6.200606
- Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73. DOI:10.31083/j. rcm2302073
- Chen J, Jiang L, Yu X, et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2022;8:798699. doi: 10.3389/fcvm.2021.798699
- Reikvam H, Hatfield K, Wendelbo O, et al. Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules. 2022;12(4):492. doi: 10.3390/biom12040492
- Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-64. doi: 10.1074/jbc.271.34.20458
- Scuruchi M, D'Ascola A, Avenoso A, et al. Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. 2021;476(3):1589-97. doi: 10.1007/s11010-020-04001-4
- Lee W, Ku S, Kim S, Bae J. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30. doi: 10.1002/jcp.24485
- Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-106. doi: 10.4049/jimmunol.167.6.3099
- Azimi A. Could “calprotectin” and “endocan” serve as “troponin of nephrologists”? Med Hypotheses. 2017;99:29-34. doi: 10.1016/j.mehy.2016.12.008
- Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol. 2022;2022:3861092. doi: 10.1155/2022/3861092
- Entezarian M, Ameli F, Masir N, Chin T. Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors. Iran J Pathol. 2022;17(2):202-9. doi: 10.30699/IJP.2022.540192.2740
- Fernández-Sarmiento J, Molina C, Salazar-Pelaez L, et al. Biomarkers of Glycocalyx Injury and Endothelial Activation are Associated with Clinical Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2023;38(1):95-105. doi: 10.1177/08850666221109186
- Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020;21(17):6119. doi: 10.3390/ijms21176119
- Kumar S, Mani K. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide. 2021;117:26-33. doi: 10.1016/j.niox.2021.09.006
- Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13407. doi: 10.1097/MD.0000000000013407
- Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients with Primary Hypertension. Angiology. 2018;69(6):483-9. doi: 10.1177/0003319717736158
- Ziaee M, Mashayekhi S, Ghaffari S, et al. Predictive Value of Endocan Based on TIMI Risk Score on Major Adverse Cardiovascular Events After Acute Coronary Syndrome. Angiology. 2019;70(10):952-9. doi: 10.1177/0003319718815241
- Kup A, Toprak C, Bayam E, et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiol Sin. 2020;36(2):111-7. doi: 10.6515/ACS.202003_36(2).20190731A
- Kose M, Emet S, Akpinar T, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727-31. doi: 10.1177/0003319714548870
- Lv Y, Zhang Y, Shi W, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Am J Med Sci. 2017;353(5):433-8. doi: 10.1016/j.amjms.2017.02.004
- Reina-Couto M, Silva-Pereira C, Pereira-Terra P, et al. Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Front Physiol. 2022;13:965611. doi: 10.3389/fphys.2022.965611
- Li C, Geng H, Ji L, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem. 2019;19:1687-94. doi: 10.2174/1871520619666190705151542
- De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. doi: 10.1186/s13054-018-2222-7
- Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87. doi: 10.2147/COPD.S118692
- Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta Rev Cancer. 2006;1765:25-37. doi: 10.1016/j.bbcan.2005.08.004
- De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013;78:45-51. doi: 10.1016/j.jpba.2013.01.035
- Gaudet A, Portier L, Mathieu D, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107:833-41. doi: 10.1002/JLB.3AB0320-612RR
- Абдурахманов З.М., Умаров Б.Я., Абдурахманов М.М. Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Рациональная фармакотерапия в кардиологии. 2021;17(4):612-8 [Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-8 (in Russian)]. doi: 10.20996/1819-6446-2021-08-08
- Turgunova L, Baidildina B, Laryushina Y, et al. Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study. Cardiol Res Pract. 2020;2020:8020674. doi: 10.1155/2020/8020674
- Ambrosino P, Bachetti T, D'Anna S, et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. doi: 10.3390/jcdd9050136
- Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. doi: 10.3389/fmed.2021.798958
- Klisic A, Kavaric N, Vujcic S, et al. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24(12):7131-7. doi: 10.26355/eurrev_202006_21707
- Balta S, Mikhailidis D, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773-7. doi: 10.1177/0003319713513492
- Oktar S, Guney I, Eren S, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2019;41(8):787-94. doi: 10.1080/10641963.2019.1652632
- Poon P, Ng J, Fung W, et al. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019;44(5):1259-70. doi: 10.1159/000502961
- Magee L, Smith G, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547-71.e1. doi: 10.1016/j.jogc.2022.03.002
- Abdull Sukor A, Ankasha S, Ugusman A, et al. Impact of offspring endothelial function from de novo hypertensive disorders during pregnancy: An evidence-based review. Front Surg. 2022;9:967785. doi: 10.3389/fsurg.2022.967785
- Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens. 2016;38(2):137-42. doi: 10.3109/10641963.2015.1060993
- Chew B, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension. J Obstet Gynaecol Res. 2019;45(2):345-51. doi: 10.1111/jog.13836
- Hentschke M, da Cunha Filho E, Vieira M, et al. Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia. Rev Bras Ginecol Obstet. 2018;40(10):593-8. doi: 10.1055/s-0038-1670713
- Hentschke M, Lucas L, Mistry H, et al. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine. 2015;74(1):152-6. doi: 10.1016/j.cyto.2015.04.013
- Yuksel M, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet. 2015;292(1):69-73. doi: 10.1007/s00404-014-3605-x
- Szpera-Goździewicz A, Kosicka K, Goździewicz T, et al. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. J Matern Fetal Neonatal Med. 2020;33(14):2313-9. doi: 10.1080/14767058.2018.1548597
- Kundi H, Gok M, Kiziltunc E, et al. The Relationship Between Serum Endocan Levels with the Presence of Slow Coronary Flow: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2017;23(5):472-7. doi: 10.1177/1076029615618024
- Ye M, Zhao Z, Luo Y, et al. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76(5):345-8. doi: 10.1080/00365513.2016.1177853
- Sığırcı S, Sarıkaya R, Keskin K, et al. Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi? Koroner yavaş akım fenomeninde endokan ve omentin-I. Turk Kardiyol Dern Ars. 2019;47(4):251-7 [Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019;47(4):251-7 (in Turkish)]. doi: 10.5543/tkda.2018.27708
- Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018;35:37-47. doi: 10.1016/j.carpath.2018.04.005
- Gök M, Kundi H, Kiziltunç E, et al. The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia. Cardiovasc Endocrinol Metab. 2018;7(2):42-6. doi: 10.1097/XCE.0000000000000143
- Turan T, Akyuz A, Aykan A, et al. Plasma Endocan Levels in Patients with Isolated Coronary Artery Ectasia. Angiology. 2016;67(10):932-6. doi: 10.1177/0003319716637789
- Xiong C, Zhao Z, Chen Z, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. J Investig Med. 2015;63(7):867-70. doi: 10.1097/JIM.0000000000000219
- Kundi H, Balun A, Cicekcioglu H, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46-51. doi: 10.1177/0003319716646932
- Qiu C, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients with Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2017;68(4):354-9. doi: 10.1177/0003319716651349
- Efe S, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. Herz. 2018;43(4):359-63. doi: 10.1007/s00059-017-4580-3
- Tunçez A, Altunkeser B, Ozturk B, et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol J Cardiol. 2019;22(5):240-9. doi: 10.14744/AnatolJCardiol.2019.64249
- Gok M, Kundi H, Kiziltunc E, et al. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-8. doi: 10.1177/0003319717703835
- Kosir G, Jug B, Novakovic M, et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure. Dis Markers. 2019;2019:9134096. doi: 10.1155/2019/9134096
- Ahmed S, Ahmed A, Bouzina H, et al. Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart Vessels. 2020;35(11):1614-28. doi: 10.1007/s00380-020-01656-3